PriceTargets.com logo

Cronos Group - CRON Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: C$3.18
  • Forecasted Upside: -20.30%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$3.99 As of 05/17/2024 01:00 AM ET
▼ -0.15 (-3.62%)

This chart shows the closing price for CRON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cronos Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRON

Analyst Price Target is C$3.18
▼ -20.30% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Cronos Group in the last 3 months. The average price target is C$3.18, with a high forecast of C$3.54 and a low forecast of C$2.82. The average price target represents a -20.30% upside from the last price of C$3.99.

This chart shows the closing price for CRON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Cronos Group. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/17/2024Jefferies Financial GroupBoost TargetC$3.23 ➝ C$3.54
1/30/2024Sanford C. BernsteinLower TargetMarket PerformC$2.84 ➝ C$2.82
11/21/2023Jefferies Financial GroupBoost TargetHoldC$2.61 ➝ C$2.72
9/18/2023Sanford C. BernsteinLower TargetMarket PerformC$3.04 ➝ C$2.84
8/16/2023Jefferies Financial GroupLower TargetC$2.63 ➝ C$2.61
6/22/2023Jefferies Financial GroupLower TargetC$3.19 ➝ C$2.63
3/2/2023Jefferies Financial GroupLower TargetC$3.60 ➝ C$3.19
3/1/2023Sanford C. BernsteinLower TargetC$3.60 ➝ C$3.42
11/8/2022MKM PartnersLower TargetC$10.00 ➝ C$7.00
9/30/2022BarclaysLower TargetNAC$5.00 ➝ C$3.50
8/12/2022Jefferies Financial GroupLower TargetC$4.30 ➝ C$3.90
8/12/2022MKM PartnersLower TargetC$11.00 ➝ C$10.00
7/29/2022Raymond JamesReiterated RatingBuyC$6.00 ➝ C$7.00
7/28/2022Canaccord Genuity GroupUpgradeBuyC$5.00
7/19/2022CowenLower TargetNAC$4.30
7/19/2022CowenLower TargetC$4.50 ➝ C$4.30
5/12/2022Jefferies Financial GroupBoost TargetC$3.70 ➝ C$4.30
5/11/2022Canaccord Genuity GroupUpgradeHoldC$4.50
5/11/2022CIBCUpgradeBuy
3/22/2022BarclaysUpgradeHoldC$5.00
3/8/2022Jefferies Financial GroupLower TargetC$4.08 ➝ C$3.70
3/7/2022Piper SandlerReiterated RatingHoldC$3.00
3/2/2022MKM PartnersReiterated RatingBuyC$11.00
2/22/2022Raymond JamesLower TargetOutperformC$6.00
1/27/2022Jefferies Financial GroupLower TargetHoldC$6.98 ➝ C$4.08
11/23/2021BarclaysReiterated RatingUnderweightC$5.00
11/18/2021BarclaysInitiated CoverageSellC$5.50
8/24/2021Raymond JamesBoost TargetOuperformC$14.00
8/11/2021Jefferies Financial GroupBoost TargetC$7.00
8/10/2021MKM PartnersLower TargetBuyC$12.00 ➝ C$11.00
6/15/2021Raymond JamesReiterated RatingOutperformC$13.00
6/7/2021Raymond JamesReiterated RatingOUTPERFORMC$13.00
5/11/2021CowenLower TargetMarket PerformC$14.00 ➝ C$9.00
5/11/2021MKM PartnersBoost TargetBuyC$11.00 ➝ C$12.00
5/10/2021Raymond JamesBoost TargetOutperformC$13.00
5/10/2021Stifel NicolausLower TargetC$12.00 ➝ C$7.50
4/9/2021Jefferies Financial GroupBoost TargetOutperformC$5.00 ➝ C$5.90
3/3/2021Raymond JamesBoost TargetOutperformC$11.00
3/2/2021Pi FinancialBoost TargetNeutralC$7.50 ➝ C$10.00
3/1/2021CowenBoost TargetC$8.00 ➝ C$14.00
11/16/2020Jefferies Financial GroupLower TargetC$5.60 ➝ C$5.00
11/9/2020Pi FinancialLower TargetNeutralC$8.50 ➝ C$7.50
8/10/2020Jefferies Financial GroupLower TargetC$6.00 ➝ C$5.60
8/7/2020Pi FinancialSet TargetNeutralC$8.50
5/12/2020Jefferies Financial GroupLower TargetC$7.00 ➝ C$6.00
5/11/2020Stifel NicolausLower TargetC$8.00 ➝ C$7.50
5/11/2020Pi FinancialLower TargetNeutralC$9.00 ➝ C$8.50
4/7/2020CowenLower TargetC$10.00 ➝ C$8.00
4/1/2020Pi FinancialDowngradeBuy ➝ NeutralC$17.00 ➝ C$9.00
3/31/2020Raymond JamesLower TargetOutperformC$12.00 ➝ C$10.50
3/4/2020Raymond JamesSet TargetOutperformC$12.00
3/4/2020MKM PartnersLower TargetBuyC$12.00 ➝ C$11.00
3/3/2020Stifel NicolausDowngradeBuy ➝ HoldC$12.00 ➝ C$8.00
2/21/2020Pi FinancialReiterated RatingBuyC$17.00
2/10/2020Raymond JamesSet TargetOutperformC$12.00
1/2/2020Jefferies Financial GroupLower TargetC$10.00 ➝ C$7.00
12/20/2019Raymond JamesReiterated RatingOutperformC$12.00
11/13/2019CIBCLower TargetC$20.00 ➝ C$17.00
10/11/2019Jefferies Financial GroupLower TargetC$15.00 ➝ C$10.00
10/4/2019CIBCLower TargetC$25.00 ➝ C$20.00
9/5/2019BMO Capital MarketsUpgradeUnderperform ➝ Market PerformC$16.00
9/3/2019CowenLower TargetC$21.00 ➝ C$17.00
6/5/2019Bank of AmericaUpgradeUnderperform ➝ BuyC$17.00 ➝ C$27.00
(Data available from 5/18/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2023
  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/17/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/17/2024

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Cronos Group logo
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Read More

Today's Range

Now: C$3.99
Low: C$3.94
High: C$4.25

50 Day Range

MA: C$3.49
Low: C$2.65
High: C$4.14

52 Week Range

Now: C$3.99
Low: C$2.15
High: C$4.28

Volume

398,692 shs

Average Volume

228,715 shs

Market Capitalization

C$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Cronos Group?

The following Wall Street research analysts have issued stock ratings on Cronos Group in the last twelve months: Jefferies Financial Group Inc., and Sanford C. Bernstein.
View the latest analyst ratings for CRON.

What is the current price target for Cronos Group?

2 Wall Street analysts have set twelve-month price targets for Cronos Group in the last year. Their average twelve-month price target is C$3.18, suggesting a possible downside of 20.3%. Jefferies Financial Group Inc. has the highest price target set, predicting CRON will reach C$3.54 in the next twelve months. Sanford C. Bernstein has the lowest price target set, forecasting a price of C$2.82 for Cronos Group in the next year.
View the latest price targets for CRON.

What is the current consensus analyst rating for Cronos Group?

Cronos Group currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRON, but not buy more shares or sell existing shares.
View the latest ratings for CRON.

What other companies compete with Cronos Group?

Other companies that are similar to Cronos Group include Canopy Growth, Hydropothecary, Tilray Brands, Knight Therapeutics and Aurora Cannabis. Learn More about companies similar to Cronos Group.

How do I contact Cronos Group's investor relations team?

Cronos Group's physical mailing address is Suite 300, Toronto, Ontario M5V 2G9. The company's listed phone number is 416-504-0004. The official website for Cronos Group is www.thecronosgroup.com. Learn More about contacing Cronos Group investor relations.